The transaction is sourced from an SEC EDGAR Form 8-K filing published on September 14, 2026. Based on the facts provided, the deal's status is pending regulatory approval.
The financial advisory arrangement on this deal is layered by committee and company. Perella Weinberg Partners LP is serving as independent financial advisor to the Special Committee of the Board of Directors of Baldwin and is identified as the lead advisor in that specific capacity. Separately, Ardea Partners LP is serving as lead financial advisor to The Baldwin Group as a whole, with MarshBerry also acting as a financial advisor to The Baldwin Group in connection with the transaction, indicating more than one advisor supporting the company-level mandate alongside the Special Committee's independent advisor.
On the legal side, Potter Anderson & Corroon LLP is serving as independent legal advisor to the Special Committee, paired with Perella Weinberg Partners in that mandate. Davis Polk & Wardwell LLP is serving as legal advisor to The Baldwin Group, paired with Ardea Partners, and Troutman Pepper Locke LLP is serving as insurance regulatory counsel to The Baldwin Group as well. On the acquirer side, Latham & Watkins LLP is acting as legal counsel to Sequence, and Sullivan & Cromwell LLP is acting as legal counsel to DFO.
Beyond confirming that this is a go-private cash merger with a disclosed value of 7,700,000,000 dollars, no further detail on the specific per-share price or other terms of the cash consideration is included in the facts available.
A number of elements of this deal are not disclosed. No financial advisor to Sequence or DFO, the acquiring parties, is identified, only their legal counsel. No expected closing date is given, and no detail on the specific per-share cash price or regulatory approvals required to close is provided in the available material.